Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
Sign Up to like & getrecommendations! Published in 2018 at "Advances in Therapy"
DOI: 10.1007/s12325-018-0689-x
Abstract: IntroductionPremenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) have complex treatment needs and may receive sequential combinations of endocrine therapy (ET) or chemotherapy. This study describes healthcare utilization… read more here.
Keywords: premenopausal women; line; first second; breast cancer ... See more keywords
Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-1164
Abstract: Purpose: The FGFR1 gene is amplified in 14% of patients with HR+/HER2− breast cancer. Efficacy and safety of lucitanib, an inhibitor of VEGFR1-3, FGFR1-3, and PDGFRα/β, were assessed. Patients and Methods: Patients with HR+/HER2− metastatic… read more here.
Keywords: her2 metastatic; patients her2; metastatic breast; cancer ... See more keywords
Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-ps5-28
Abstract: Background: Three CDK 4/6 inhibitors (inh) are FDA approved in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC), however, there are no validated predictive markers of response to this class of drugs.… read more here.
Keywords: her2 metastatic; metastatic breast; cdk drug; cancer ... See more keywords
Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.1001
Abstract: 1001 Background: Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC) in phase 1/2 trials. Methods: This double-blinded, multicentre, randomised phase… read more here.
Keywords: her2 metastatic; metastatic breast; pyrotinib; previously treated ... See more keywords
HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
Sign Up to like & getrecommendations! Published in 2022 at "Life"
DOI: 10.3390/life12091403
Abstract: Simple Summary In the current clinical practice, HER2 status is tested in breast and gastroesophageal cancers to select patients eligible for anti-HER2 treatment. However, HER2 is an emerging biomarker in colorectal cancer (CRC), one of… read more here.
Keywords: her2; pathology; crc; her2 metastatic ... See more keywords